Businessweek

Cellceutix Corporation, an early stage developmental biopharmaceutical company, develops pharmaceutical compound candidates that are designed for treatment of diseases. Pharmaceutical Compound Candidates Kevetrin: The company’s main product candidate includes Kevetrin. There is a potential for use of Kevetrin in multiple tumor types. The company has conducted pre-clinical studies in lung cancer, head and neck cancer, colon cancer, breast cancer, prostate cancer, pancreatic cancer and in leukemia models. Kevetrin is being developed as an intravenous (IV) infusion therapy (the giving of the drug directly into the vein). As of June 21, 2012, the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for Kevetrin. KM-133: KM-133, a small molecule compound, acting on the principles of folate mechanism, is in development for Psoriasis. After a series of chemical optimization exercises, the company has completed an animal study in a xenograft model of psoriasis. KM 391: KM-391 is a small molecule being developed for autism. The company has completed three animal studies with KM -391. KM 277: The company develops this compound for the treatment of Arthritis. KM 278: KM 278 was tested against standard treatment for asthma and Osteoarthritis. KM-362: This compound aids in demyelination (the loss of nerve fiber ‘insulation’ due to trauma or disease, which reduces the ability of nerves to conduct impulses) along with strengthening the functions of the nerves, spinal chord and the brain tissue. KM-3174: This is a very early stage developmental compound in the treatment of cancer. KM-732: This is a very early-stage developmental compound with potential for the treatment of hypertensive emergency. Intellectual Property The company has been assigned all right title and interest to the following eight pharmaceutical compounds: Kevetrin, KM 277, KM 278, KM 133 KM 362, KM 3174, KM 732, and KM-391 by their inventors. In May 2009, the company filed a U.S. patent application covering pharmaceutical formulations of Kevetrin and other novel compounds having similar structures to Kevetrin that may have potential as drug development candidates. The application also covers the use of Kevetrin and the other related compounds in various areas, including cancers. In May 2010, the company filed foreign patent applications and a further United States application covering similar subject matter. The foreign applications cover Patent Cooperation Treaty (PCT) countries, as well as key non-PCT countries. In January 2012, the company filed a U.S. patent application covering the pharmaceutical formulation of Prurisol, also known as KM-133, a compound to treat psoriasis. Strategy The company’s strategy is to use its business and scientific expertise to maximize the value of its pipeline by focusing initially on its compounds, Kevetrin and Prurisol and advancing them as quickly as possible along the regulatory pathway. History Cellceutix Corporation was founded in 2007.